Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Craig Venter Wants To Extend Your Life (And Own Your Data)

This article was originally published in Start Up

Executive Summary

The onetime Celera CEO says his new attempt to centralize biological information into a massive database could lead to breakthroughs that extend the human life span. Behind that bold goal is a more mundane data-licensing strategy that, although not splashy, could still improve medicine.

You may also be interested in...



Google-Backed Calico Project Will Investigate Anti-Aging Technologies

The Internet search and advertising giant has tapped Genentech and Apple chairman Art Levinson to lead a new initiative that will explore aging and related diseases. Google will invest an undisclosed amount to launch the latest Silicon Valley-funded effort to extend human longevity.

Discredited SIRT1 Stops DNA Damage In Neurons

SIRT1, the molecule activated by the controversial anti-aging supplement resveratrol, has been among the most disappointing of drug targets but now, research has linked it, along with the enzyme HDAC1, to the ability to stabilize the genome following DNA damage. The work is encouraging for the development of activators of SIRT1 and HDAC1 as neuroprotectants and DNA repair agents.

Deals of the Week Takes Stock In M&A

Do high biotech share prices portend stock-heavy deal-making in lieu of all-cash transactions? Also, Biogen shares the risk with Eisai in an Alzheimer’s deal, while newly public Genocea and cell therapy specialist NeoStem both teamed with Harvard researchers.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC092594

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel